Search #ABSTRACT#
Merck KGaA's U.S. Affiliate Dey Names Mel Engle as New President and CEO
Darmstadt, Germany, and Napa, CA, October 17, 2002 - Dey L.P., a specialty pharmaceutical company focused on prescription drug products for the treatment of selected respiratory diseases and allergies, announced on October 17, 2002, the appointment of Mel Engle as the Company's new President and Chief Executive Officer. Dey is an U.S. affiliate of Merck KGaA.
Engle has served as the Chief Operating Officer at Dey since January of this year. He brings 23 years of domestic and international senior management experience in the pharmaceutical and medical device industry. Prior to joining Dey, Mr. Engle was Chairman, President and CEO of Anika Therapeutics, Inc.
"I am thrilled at the opportunity to become the CEO of Dey," said Mr. Engle. "Through teamwork, innovation, communication and working toward common goals, I am confident Dey can be successful in providing and developing the highest quality respiratory pharmaceutical products for its customers."
Mr. Engle's background includes 14 years with Allergan, Inc. where he held positions of Managing Director of Canadian Operations (located in Toronto), Senior Vice President of Latin America and Canada, Senior Vice President of U.S. Sales, and Chief Financial Officer.
Mr. Engle holds an MBA from the University of Southern California and a BS degree from the University of Colorado. He is a member of the Thunderbird Global Council at the American Graduate School of International Management. "It is a dynamic time in the company's history when we face multiple opportunities and multiple challenges," said Mr. Engle. "While building from the past, I am committed to developing and executing a strategic direction for Dey that will make the company a growing force in the pharmaceutical industry."
Mr. Engle also credited the out-going CEO and President, Charles Rice, with its success over the last 15 years. "Dey would not have been able to grow its sales 15-fold over the last 10 years, expanding the workforce to over 1,000 people without the leadership and vision of Charles Rice," said Mr. Engle. "He has established a strong foundation of excellence at Dey that will serve us well as we move forward."
While operational control of the company will now reside with Engle, Rice and Engle will serve as co-CEOs through November 15 of this year, at which time Rice will step down from his current position.
